The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Stryker's revenues will grow 1.9% and EPS will expand 7.7%.
The average estimate for revenue is $2.07 billion. On the bottom line, the average EPS estimate is $0.98.
Last quarter, Stryker notched revenue of $2.11 billion. GAAP reported sales were 2.9% higher than the prior-year quarter's $2.05 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.98. GAAP EPS of $0.85 for Q2 were 7.6% higher than the prior-year quarter's $0.79 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 68.2%, 40 basis points better than the prior-year quarter. Operating margin was 22.6%, 10 basis points worse than the prior-year quarter. Net margin was 15.4%, 20 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $8.63 billion. The average EPS estimate is $4.09.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,454 members out of 1,486 rating the stock outperform, and 32 members rating it underperform. Among 430 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 421 give Stryker a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stryker is outperform, with an average price target of $61.10.
- Add Stryker to My Watchlist.